9 April 2018 - - Beltsville, Maryland-based biopharmaceutical company NextCure, Inc. has appointed Kevin N. Heller, M.D., as chief medical officer and Steve Cobourn, CPA, as chief financial officer, the company said.
Most recently Heller was vice president, head of mAb clinical development, immuno-oncology at Incyte Corp. where he led the clinical development of Incyte's monoclonal antibody programs for cancer immunotherapy. He was also chair of Incyte's Immunotherapy strategy team.
Prior to joining Incyte, Heller was the senior medical director for oncology at AstraZeneca where he led late stage clinical development programs. He also held various positions at Bristol-Myers Squibb where he was director, US medical lead for ipilimumab and global lead, oncology, strategic transactions group.
He received his M.D. from George Washington University and B.S. in Molecular Biophysics and Biochemistry from Yale University.
Cobourn has more than 20 years of experience in life sciences including financing, product launches, alliances, and operations. Previously, he was the chief financial officer of Vaccinex, Inc., a privately held clinical-stage biotechnology company.
Prior to joining Vaccinex, Cobourn was vice president of Finance, treasurer, and corporate officer of Otsuka America Pharmaceutical, Inc., the US division of publicly traded Otsuka Holdings Co., Ltd.
He received his B.S. in Business Administration from Drexel University and is a Certified Public Accountant in the State of Pennsylvania.
NextCure is focused on discovering and developing next generation first-in-class immunotherapy-based biologics for cancer and other diseases.
The company leverages its FIND-IO technology to discover, validate and build a proprietary pipeline of novel immunotherapy targets.